Antibodies

19 June 2013

Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma

19 June 2013

Celltrion files for approval of CT-P6, breast cancer mAb biosimilar, in Korea

19 June 2013

RemsimaTM extended clinical trial study was disclosed in EULAR 2013

17 June 2013

Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013

17 June 2013

Karolinska Development AB (publ): EU grants EUR 6m to the clinical development of Athera´s cardiovascular disease antibody therapy

15 June 2013

Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma

14 June 2013

FDA Approves Amgen’s XGEVA (denosumab) For The Treatment Of Giant Cell Tumor Of Bone

13 June 2013

Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program

13 June 2013

STELARA® Phase 3 Study Published In The Lancet Reports One Year Efficacy And Safety In Treatment Of Active Psoriatic Arthritis

13 June 2013

XOMA Initiates Pilot Trial Studying Gevokizumab in Patients With Pyoderma Gangrenosum

13 June 2013

Immunomedics Reports Progress With Labeling Proteins, Including Antibodies, for Improved PET Imaging

13 June 2013

AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA® (adalimumab) for Rheumatoid Arthritis

13 June 2013

Roche’s RoACTEMRA shows long-term efficacy in monotherapy and also benefits in early rheumatoid arthritis

12 June 2013

Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer

12 June 2013

Teprotumumab Restarts Clinical Development in New Indication

12 June 2013

ORENCIA (abatacept) Shows Comparable Efficacy to Humira (adalimumab) in Year Two Data from Head-to-Head Study in Patients with Moderate to Severe Rheumatoid Arthritis

11 June 2013

90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R-CHOP

11 June 2013

Combination of 90Y-Epratuzumab and Veltuzumab is Active in Non-Hodgkin Lymphoma

10 June 2013

Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial Relapse

10 June 2013

Roche’s RoACTEMRA approved in EU to treat children with rare form of arthritis

8 June 2013

The Angeles Clinic and Research Institute Presents Promising New Data on Clinical Activity, Safety and Biomarkers of MPDL3280A, an Engineered PD-L1 Antibody in Patients with Metastic Melanoma

8 June 2013

Avaxia Biologics Closes Series B Financing with Total Proceeds of $11.4 Million

6 June 2013

Regeneron and Bayer Report Positive Phase 3 Results for EYLEA (aflibercept) Injection in Myopic Choroidal Neovascularization (mCNV)

4 June 2013

Precision Biologics Presents Phase 2A Data to American Society of Clinical Oncology

4 June 2013

ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein

3 June 2013

Data Presented at ASCO Shows Promising 11.7 Month Median Overall Survival in Second-Line NSCLC Patients Treated With Peregrine Pharmaceuticals’ Novel Immunotherapy Bavituximab

3 June 2013

First Clinical Data Presented with IMGN853, ImmunoGen, Inc.’s Potential New Therapy for Ovarian and Other Cancers

3 June 2013

OncoMed Pharmaceuticals Presents Phase 1 Data in Solid Tumor Patients for the First-in-Class Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5) at ASCO

3 June 2013

Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy (ipilimumab), in Patients with Advanced Melanoma

2 June 2013

Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

c-Met-Targeted Antibody Therapy Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review

TL1A Inhibitor Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Report Package: Bispecific Antibodies

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

TSLP Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review